<?php
include_once('.././common.php');
include_once(G5_PATH . '/head.php');
?>

<div id="providers" class="sub02">
    <section class="sub-visual visual02">
        <div class="visual-txt">
            <h2><?= $title ?></h2>
        </div>
    </section>
    <!--sub-visual-->
    <section class="top el">
        <div class="inner">
            <h2 class="cont-tit">Clinical Development Programme<sup class="small-sup">1-9</sup>
            </h2>
            <div class="explan">
                <p>Learn more about the clinical studies for regdanvimab as well as <em>in
                        vitro</em> and <em>in vivo</em> animal analyses against emerging
                    SARS-CoV-2 variants
                    below.</p>
            </div>
            <div class="cont-sec">

                <table class="table-style01">
                    <thead>
                        <tr>
                            <th>Healthy subjects</th>
                            <th colspan="3">Patients with mild-to-moderate COVID-19</th>
                            <th><em>In vitro</em> and <em>in vivo</em> (animal)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td class="cate">Healthy volunteer study (Phase 1)</td>
                            <td class="cate">Mild COVID-19 study <br />(Phase 1)</td>
                            <td class="cate" colspan="2">Global pivotal study (Phase 2/3)</td>
                            <td class="cate">Neutralising capability against emerging variants</td>
                        </tr>
                        <tr>
                            <td class="cate2">Dose Finding</td>
                            <td class="cate2">Dose Finding</td>
                            <td class="cate2">Part1</td>
                            <td class="cate2">Part2</td>
                            <td class="cate2">-</td>
                        </tr>
                        <tr>
                            <td>Regdanvimab was well tolerated in healthy subjects (N = 32).</td>
                            <td>Regdanvimab was well tolerated in patients with mild COVID-19 (N = 18)</td>
                            <td>Regdanvimab reduced progression rates to severe COVID-19<sup>* </sup>by 54% for patients
                                with mild-to-moderate symptoms; and by 68% for patients with moderate symptoms aged 50
                                years and over vs placebo (N = 327)</td>
                            <td>Progression of COVID-19 at Day 28 was reduced by 72% in high-risk
                                patients<sup>&dagger;</sup> treated with regdanvimab compared to placebo (p&lt;0.0001)
                                (N = 880)</td>
                            <td><em>In vitro</em> and <em>in vivo</em> animal tests demonstrated regdanvimab retained
                                neutralising potency against variants of concern including Alpha (B.1.17), Beta
                                (B.1.351), Gamma (P.1) and Delta (B.1.167.2)</td>
                        </tr>
                        <tr>
                            <td><a class="detail-btn" href="#sec01">See Details</a></td>
                            <td><a class="detail-btn" href="#sec02">See Details</a></td>
                            <td><a class="detail-btn" href="#sec03">See Details</a></td>
                            <td><a class="detail-btn" href="#sec04">See Details</a></td>
                            <td><a class="detail-btn" href="#sec05">See Details</a></td>
                        </tr>
                    </tbody>
                </table>
                <br>
                <div class="extranote">
                    <p><sup>* </sup>Defined as clinical symptoms requiring hospitalisation, oxygen therapy, or
                        experiencing
                        mortality due to SARS-CoV-2 infection up to Day 28.</p>
                    <p><sup>&dagger;</sup>Defined as having at least one of the following risk factors for severe
                        COVID-19: age &gt;50 years; BMI &gt;30 kg/m2; cardiovascular disease, including
                        hypertension; chronic lung disease, including asthma; type 1 or type 2 diabetes mellitus;
                        chronic kidney disease, including those on dialysis; chronic liver disease; and
                        immunosuppressed, based on investigator&rsquo;s assessment.</p>
                </div>
                <br>
                <div class="reference">
                    <span class="ref-tit">References</span>: <strong>1.</strong> Kim JY, <em>et al. </em><em>Clin.
                        Ther.</em> 2021&nbsp;;43(10): 1706-1727. <strong>2.</strong> Eom J, <em>et al.</em> Therapeutic
                    effect of regdanvimab (CT-P59) in patients with mild to moderate symptoms of SARS CoV-2 infection:
                    Day 28 results from a multicentre, randomised controlled pivotal trial. 2020 High1 Symposia; Limited
                    Access. <strong>3.</strong> Ison MG, <em>et al.</em> Therapeutic effect of regdanvimab (CT-P59) in
                    patients with mild to moderate symptoms of SARS CoV-2 infection: Day 28 results from a multicentre,
                    randomised controlled pivotal trial. Presented at Keystone Symposia, January 13, 2021, virtual
                    platform. Available at: <a href="https://virtual.keystonesymposia.org/ks/sessions/6866/view"
                        target="_blank" rel="noopener">https://virtual.keystonesymposia.org/ks/sessions/6866/view</a>.
                    <strong>4.</strong> Ison MG, <em>et al.</em> Therapeutic effect of regdanvimab in patients with mild
                    to moderate COVID-19: day 28 results from a multi-centre, randomised, controlled pivotal trial.
                    Presented at the 31st European Congress of Clinical Microbiology &amp; Infectious Diseases, July
                    9-12, 2021, Vienna, Austria. <strong>5.</strong> Data on file. Celltrion Healthcare.
                    <strong>6.</strong> Ryu DK, <em>et al. Biochem. Biophys. </em><em>Res. Commun.</em>
                    2021;566:135-140. <strong>7.</strong> Ryu DK, <em>et al. bioRxiv.,</em> [Preprint] <a
                        href="https://doi.org/10.1101/2021.07.08.451696" target="_blank"
                        rel="noopener">https://doi.org/10.1101/2021.07.08.451696</a>. <strong>8.</strong> Ryu DK, <em>et
                        al. bioRxiv.,</em> [Preprint] <a href="https://doi.org/10.1101/2021.07.23.453472"
                        target="_blank" rel="noopener">https://doi.org/10.1101/2021.07.23.453472</a>.
                    <strong>9.</strong> Celltrion Healthcare Australia Pty Ltd. REGKIRONA Approved Product Information.
                    December 6, 2021.
                </div>


            </div>
        </div>
    </section>
    <!--top-->
    <section id="sec01" class="cont-a el">
        <div class="inner">
            <h2 class="cont-tit">Phase 1 healthy volunteer study (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT04525079"
                    style="text-decoration:underline #302f86; color: #302f86;" target="_blank">NCT04525079</a>)<span
                    class="s-num">1</span></h2>
            <div class="cont-sec">
                <h3 class="sub-tit">Study Design</h3>
                <ul class="cont-list cont-indt">
                    <li>A phase 1, randomised, double-blind, placebo-controlled, parallel-group, single ascending dose
                        study
                    </li>
                </ul>
            </div>
            <h3 class="img-title text-center"><b>Healthy volunteers</b> (N = 32) </h3>
            <div class="img-sec">
                <img src="/img/providers/des_img-1-1.png">
                <div class="extranote">
                    <p>*Reviewed and approved by the Dose Escalation Committee <br>
                        &dagger;Regdanvimab is not approved for use at doses of 10, 20 mg/kg and 80 mg/kg2</p>
                </div>
            </div>
            <div class="cont-sec">
                <h3 class="sub-tit">Primary Objective</h3>
                <div class="cont-indt">
                    <div class="cont-box">
                        <ul class="cont-list">
                            <li>To evaluate the preliminary <b>safety and tolerability</b>
                                of regdanvimab up to Day 14 of the last enrolled subject
                            </li>
                        </ul>
                    </div>
                </div>
            </div>
            <div class="cont-sec">
                <h3 class="sub-tit">Primary Endpoint</h3>
                <div class="cont-indt">
                    <div class="cont-box">
                        <ul class="cont-list">
                            <li>Overall safety outcomes at Day 14</li>
                            <li>Treatment-emergent adverse events (TEAEs)</li>
                            <li>Treatment-emergent serious AEs (TESAEs)</li>
                            <li>TEAEs of special interest (TEAESI; infusion-related reactions including
                                hypersensitivity/anaphylactic reaction)
                            </li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
        <!---->
        <section class="cont-b">
            <div class="inner">
                <h3 class="sub-tit">Study Results</h3>
                <h3 class="sub-tit3">Study Population</h3>
                <div class="cont-indt">
                    <div class="cont-box">
                        <ul class="cont-list">
                            <li>Overall, the demographics were well matched between treatment
                                groups
                            </li>
                            <li>All subjects were male and Asian (N = 32; 100%). The median age was 24 years
                            </li>
                        </ul>
                    </div>
                </div>
                <h3 class="sub-tit3">Safety</h3>
                <div class="cont-indt">
                    <div class="cont-box">
                        <ul class="cont-list">
                            <li>A total of 4 TEAEs were reported in 4 subjects (n = 4; 12.5%)
                                up to Day 14 of the last enrolled subject (regdanvimab, n = 3;
                                placebo, n = 1)
                            </li>
                            <li>All TEAEs were considered related to study treatment, grade 1
                                in intensity and recovered
                            </li>
                            <li>There was 1 TEAESI (infusion-related reaction) in cohort 3 (n = 1; 12.5%)
                            </li>
                            <li>There were no TESAEs or AEs leading to study discontinuation
                            </li>
                            <li>Overall, regdanvimab was well tolerated in the study population of healthy subjects
                            </li>
                        </ul>
                    </div>
                    <p class="abbreviations"><b>AE,</b> adverse event;&nbsp;<b>TEAE,</b>
                        treatment-emergent adverse event; <b>TEAESI,</b> treatment-emergent adverse event of
                        special interest; <b>TESAE, </b>treatment-emergent serious adverse event.</p>
                    <br><br>
                    <div class="reference">
                        <span class="ref-tit">References</span>: <b>1</b>. Kim JY, <em>et al. </em><em>Clin. Ther.</em>
                        2021&nbsp;;43(10): 1706-1727.
                        <b>2</b>. Celltrion Healthcare Australia Pty Ltd. REGKIRONA Approved Product Information.
                        December 6, 2021.
                    </div>
                </div>

            </div>
        </section>
        <!--cont-b-->
    </section>
    <!--sec01-->
    <section id="sec02" class="cont-c el">
        <div class="inner">
            <h2 class="cont-tit">Phase 1 Mild COVID-19 Study (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT04593641?cond=NCT04593641&draw=2&rank=1"
                    style="text-decoration:underline #302f86; color: #302f86;" target="_blank">NCT04593641</a>)<span
                    class="s-num">1</span></h2>
            <div class="cont-sec">
                <h3 class="sub-tit">Study Design</h3>
                <ul class="cont-list cont-indt">
                    <li>A pilot phase 1, randomised, double-blind, placebo-controlled, parallel-group, single ascending
                        dose study
                    </li>
                </ul>
            </div>
            <h3 class="img-title text-center"><b>
                    Patients with mild COVID-19
            </h3>
            <div class="img-sec">
                <img src="/img/providers/des_img-1-2.png">
                <div class="cont-indt extranote fw-n">
                    <p>*Reviewed and approved by the Dose Escalation Committee <br> &dagger;Regdanvimab is not approved
                        for use at doses of 20 mg/kg and 80 mg/kg2</p>
                </div>

            </div>
            <!--Study Design-->
            <div class="cont-sec">
                <h3 class="sub-tit">Objectives</h3>

                <div class="cont-box cont-indt fw-n">
                    <ul class="cont-list">
                        <li>Primary objective: To evaluate the preliminary <b>safety and
                                tolerability</b> of regdanvimab up to Day 14 of the last
                            enrolled patient
                        </li>
                        <li>Secondary objectives: To evaluate the&nbsp;<b>viral efficacy and characterisation of
                                SARS-CoV-2 viral isolates, clinical efficacy, pharmacokinetics (PK) and additional
                                safety</b>of regdanvimab, including immunogenicity
                        </li>
                    </ul>
                </div>

            </div>
            <!--Objectives-->
            <div class="cont-sec ">
                <h3 class="sub-tit">Primary endpoints</h3>
                <div class="cont-box cont-indt fw-n">
                    <ul class="cont-list">
                        <li>Overall safety outcomes at Day 14</li>
                        <li>Treatment-emergent adverse events (TEAEs)</li>
                        <li>Treatment-emergent serious AEs (TESAEs)</li>
                        <li>TEAEs of special interest (TEAESI; infusion related reactions including
                            hypersensitivity/anaphylactic reaction)</li>
                    </ul>
                </div>
            </div>
            <!--Primary Endpoints-->
            <div class="cont-sec">
                <h3 class="sub-tit">Key secondary endpoints</h3>
                <div class="cont-box cont-indt fw-n">
                    <ul class="cont-list">
                        <li>Virology: viral shedding in nasopharyngeal swab specimens based on quantitative polymerase
                            chain reaction (qPCR) and cell culture assessments</li>
                        <li>Efficacy: time to clinical recovery up to Day 28</li>
                    </ul>
                </div>
            </div>
            <!--Key Secondary Endpoints-->
        </div>
        <!---->
        <section class="cont-d fw-n">
            <div class="inner">
                <div class="cont-sec">
                    <h3 class="sub-tit"><b>Study results</b><sup>1</sup></h3>
                    <h3 class="sub-tit3">Study population</h3>
                    <div class="cont-box cont-indt">
                        <ul class="cont-list">
                            <li>The overall demographics were well matched between treatment groups; however, the median
                                age was slightly higher in the regdanvimab 20 mg/kg group (59.0 years vs 52.0 years in
                                all patients)</li>
                            <li>All patients who received regdanvimab 20 mg/kg (n=5) were Asian, and all patients who
                                received 40 mg/kg (n=5) or 80 mg/kg (n=5) were Caucasian</li>
                        </ul>
                    </div>
                </div>
                <!--Study Demographics-->
                <div class="cont-sec">
                    <h3 class="sub-tit3">Safety</h3>
                    <div class="cont-box cont-indt">
                        <ul class="cont-list">
                            <li>A total of 19 AEs were reported in 11 subjects (n = 11 [61.1%]) up to Day 14 of the last
                                enrolled patient</li>
                            <li>All AEs were considered unrelated to the study drug</li>
                            <li>There were no SAEs, AESI or AEs leading to study discontinuation</li>
                            <li>Overall, regdanvimab was well tolerated in this study population of patients with mild
                                SARS-CoV-2 infection</li>
                        </ul>
                    </div>
                </div>
                <!--Safety-->
                <div class="cont-sec">
                    <h3 class="sub-tit3"><b>Time to clinical recovery up to day 14</b><sup>1</sup></h3>
                    <div class="cont-box cont-indt">
                        <ul class="cont-list">
                            <li>The mean time to clinical recovery was <b>5.25</b> days in the placebo cohort and <b>3.21</b> days in
                                the regdanvimab 40 mg/kg cohort</li>
                        </ul>
                        <div class="table-wr">
                            <table class="table-style02">
                                <thead>
                                    <tr>
                                        <th colspan="2">Category</th>
                                        <th>Placebo<br />(N=3)</th>
                                        <th>Regdanvimab<br />20 mg/kg*<br />(n = 5)</th>
                                        <th>Regdanvimab<br />40 mg/kg <br />(n = 5)</th>
                                        <th>Regdanvimab<br />80 mg/kg* <br />(n = 5)</th>
                                        <th>Total<br />(N=18)</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td class="cate"><b>Age(years)</b></td>
                                        <td class="cate">Median (IQR)</td>
                                        <td>50.0 (49&ndash;57)</td>
                                        <td>59.0 (56&ndash;59)</td>
                                        <td>51.0 (48&ndash;52)</td>
                                        <td>52.0 (43&ndash;57)</td>
                                        <td>52.0 (49&ndash;57)</td>
                                    </tr>
                                    <tr>
                                        <td class="cate"><b>Time from symptom onset to study
                                                drug<br />administration (days)</b></td>
                                        <td class="cate">Median (IQR)</td>
                                        <td bgcolor="#f7f7f7">4.0 (4&ndash;6)</td>
                                        <td bgcolor="#f7f7f7">4.0 (3&ndash;5)</td>
                                        <td bgcolor="#f7f7f7">6.0 (5&ndash;6)</td>
                                        <td bgcolor="#f7f7f7">4.0 (4&ndash;4)</td>
                                        <td bgcolor="#f7f7f7">4.0 (4&ndash;5)</td>
                                    </tr>
                                    <tr>
                                        <td class="cate" rowspan="2"><b>Time to clinical
                                                recovery</b><sup>&Dagger;</sup><b> (days)</b></td>
                                        <td class="cate">Mean (SD)</td>
                                        <td>5.25 (6.732)</td>
                                        <td>4.43 (2.277)</td>
                                        <td>3.21 (3.243)</td>
                                        <td>2.52 (1.753)</td>
                                        <td>&ndash;</td>
                                    </tr>
                                    <tr>
                                        <td class="cate">Median (IQR)</td>
                                        <td>2 (1&ndash;18)</td>
                                        <td>4.0 (2.0&ndash;7.5)</td>
                                        <td>2.0 (0.5&ndash;8.5)</td>
                                        <td>3.5 (1.5, 5.5)</td>
                                        <td>3.5 (0.5&ndash;8.5)</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                        <p class="extranote">IQR, interquartile range; SD, standard deviation. <br><br>
                            <sup>*</sup>Regdanvimab is not approved for use at doses of 20 mg/kg and 80
                            mg/kg.<sup>2</sup><br>
                            <sup>&dagger;</sup>Number of days is calculated as [date of study drug administration
                            &minus; first start date of SARS-CoV-2 infection-associated symptoms + 1].
                            <br><sup>&Dagger;</sup>Clinical recovery is defined as all symptoms on the SARS-CoV-2
                            Infection Symptom Checklist are recorded as &lsquo;absent or mild in intensity&rsquo; for at
                            least 24 hours (measures the patient&rsquo;s self-awareness of 7 COVID-19 symptoms)
                        </p>

                    </div>
                </div>
                <!---->
                <div class="cont-sec">
                    <h3 class="sub-tit3">Viral shedding based on qPCR up to Day 7 (N = 18)</h3>
                    <div class="cont-box cont-indt">
                        <ul class="cont-list">
                            <li>Nasopharyngeal swabs were analysed using qPCR to measure changes in viral shedding from
                                baseline through to Day 7</li>
                            <li>In patients with maximum viral titre of &gt;10<sup>5</sup> copies/mL, decrease in viral
                                load was more rapid among patients receiving regdanvimab, compared with placebo&nbsp;
                                showed greater reductions in viral shedding up to Day 7 after receiving regdanvimab vs
                                placebo</li>
                        </ul>
                        <br><br>
                        <p style="text-align: center;"><b>Viral shedding by maximum viral titre and treatment</b></p>

                        <div class="img-sec"><img src="/img/providers/graph-01-new.png">
                        </div>

                        <p>Change in viral titer according to maximum viral load (A) <em>&lt; </em>10<sup>5</sup> copies
                            (cp)/mL, (B) <em>&gt; </em>10<sup>5</sup> cp/mL, (C)&nbsp;<em>&gt; </em>10<sup>6</sup>
                            cp/mL, and (D) <em>&gt; </em>10<sup>7</sup> cp/mL in patients with mild SARS-CoV-2 infection
                            (study 1.2). Dotted horizontal lines represent lower limit of detection.</p>

                        <div class="table-wr">

                            <p class="abbreviations"><b>AE, adverse event; PK, </b>pharmacokinetic;<b>
                                    qPCR,</b> quantitative polymerase-chain-reaction; <b>TEAE,
                                </b>treatment-emergent adverse event;<b> TEAESI, </b>treatment-emergent
                                adverse event of special interest.</p>
                        </div>

                        <div class="reference">
                            <span class="ref-tit">References</span>: <b>1.</b> Kim JY, <em>et al.
                            </em><em>Clin. Ther.</em> 2021;43(10): 1706-1727. <b>2.</b>Celltrion Healthcare
                            Australia Pty Ltd. REGKIRONA Approved Product Information. December 6, 2021.
                        </div>

                    </div>
                </div>
            </div>
        </section>
        <!--cont-d-->
    </section>
    <!--sec02-->
    <section id="sec03" class="cont-e el fw-n">
        <div class="inner">
            <h2 class="cont-tit">Part 1 of Phase 2/3 Global Pivotal Study (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT04602000?cond=CT-P59&draw=2&rank=2"
                    style="text-decoration:underline #302f86; color: #302f86;" target="_blank">NCT04602000</a>)<span
                    class="s-num">1, 2</span></h2>
            <p>The approval of regdanvimab was based on interim data from this Phase 2 study.</p>
            <p>&nbsp;</p>
            <div class="cont-sec">
                <h3 class="sub-tit">Study Design</h3>
                <div class="cont-indt">
                    <ul class="cont-list">
                        <li>A randomised, parallel-group, placebo-controlled, double-blind study of patients with
                            mild-to-moderate COVID-19 (N = 327)</li>
                        <li>Aim: to evaluate the efficacy and safety of regdanvimab in combination with standard of care
                            in outpatients with SARS-CoV-2 infection</li>
                    </ul>
                    <div class="img-sec mgt20"><img src="/img/providers/part_img01.png">
                    </div>
                    <br>
                    <div class="extranote">
                        <p>SoC, standard of care.<br />&dagger;Regdanvimab is
                            not approved for use at doses of 80 mg/kg3</p>
                    </div>

                </div>
            </div>
            <!--Study Design : Part 1-->
            <div class="cont-sec">
                <h3 class="sub-tit">Primary Endpoints</h3>
                <div class="cont-box cont-indt">
                    <ul class="cont-list">
                        <li>patients with clinical symptoms requiring hospitalisation, oxygen therapy or death due to
                            SARS-CoV-2 infection up to Day 28 in high-risk patients<sup>*</sup></li>
                    </ul>
                </div>
                <div class="cont-indt extranote">
                    <p><sup>*</sup>Defined as having at least one of the
                        following risk factors for severe COVID-19: age &gt;50 years; BMI &gt;30 kg/m<sup>2</sup>;
                        cardiovascular disease, including hypertension; chronic lung disease, including asthma; type 1
                        or type 2 diabetes mellitus; chronic kidney disease, including those on dialysis; chronic liver
                        disease; and immunosuppressed, based on investigator&rsquo;s assessment</p>
                </div>
            </div>
            <!--Primary Endpoints-->
            <div class="cont-sec">
                <h3 class="sub-tit">Eligibility criteria UP TO HERE</h3>
                <div class="cont-box cont-indt">
                    <div class="dia-wr">
                        <div class="list">
                            <p class="tit01">Key inclusion criteria</p>
                            <ul class="cont-list">
                                <li>Adult male or female <b>(</b><b>&ge; 18 years)</b></li>
                                <li><b>SARS-CoV-2</b> diagnosis</li>
                                <li>Oxygen saturation&nbsp;<b>&gt;94%</b> and&nbsp;<b>not requiring
                                        supplemental oxygen</b>.&nbsp;Patients with clinical signs of pneumonia but
                                    no signs of severe pneumonia were eligible at the investigator&rsquo;s discretion
                                </li>
                                <li><b>Symptom onset within 7 days </b></li>
                                <li>Patients with &ge;1 of the following (but not limited to) SARS-CoV-2-associated
                                    symptoms within &le;7 days prior to study drug administration:</li>
                                <li class="blt-none">
                                    <ul class="s-cont-list">
                                        <li class="bt-none">
                                            - Fever<br>
                                            - Cough<br>
                                            - Shortness of breath<br>
                                            - Sore throat
                                        </li>
                                        <li class="bt-none">
                                            - Body or muscle pain<br>
                                            - Fatigue<br>
                                            - Headache
                                        </li>
                                    </ul>
                                    <!--s-cont-list-->
                                </li>
                            </ul>
                            <!--cont-list-->
                        </div>
                        <div class="list">
                            <p class="tit02">Key exclusion criteria</p>
                            <ul class="cont-list">
                                <li><b>Serious conditions</b>(previously or currently hospitalised, or
                                    requiring hospitalisation for treatment of serious SARS-CoV-2-related conditions,
                                    respiratory distress with respiratory rate &ge; 30 breaths/min, requiring
                                    supplemental oxygen, in shock, complicated with other organ failure and requiring
                                    Intensive Care Unit (ICU) treatment, or any other conditions suspected of being
                                    severe symptoms of SARS-CoV-2)</li>
                                <li>Has received/plans to&nbsp;<b>receive any prohibited medications or
                                        treatments</b></li>
                                <li><b>Known allergy or hypersensitivity reaction to any monoclonal
                                        antibody</b>or to any components of the study drug</li>
                            </ul>
                            <!--cont-list-->
                        </div>
                    </div>
                </div>
            </div>
            <!--Eligibility Criteria-->
            <div class="cont-sec">
                <h3 class="sub-tit">Study Results</h3>
                <h3 class="sub-tit3 cont-indt">Key Demographic Information: Intent-to-Treat Infected (ITTI) set.</h3>
                <div class="cont-box cont-indt">
                    <ul class="cont-list">
                        <li>Approximately 60% of participants had moderate COVID-19 symptoms and pneumonia</li>
                    </ul>
                    <div class="table-wr">
                        <table class="table-style01">
                            <thead>
                                <tr>
                                    <th>N(%)</th>
                                    <th>Total*<br>(N=307)</th>
                                    <th>Regdanvimab<br>40 mg/kg<br>(N=101)</th>
                                    <th>Regdanvimab<br>80 mg/kg<br>(N=103)</th>
                                    <th>Regdanvimab<br>Total<br>(N=204)</th>
                                    <th class="style02">Placebo<br>(N=103)</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td class="cate" colspan="6">Disease Severity</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Mild</td>
                                    <td>125(40.7)</td>
                                    <td>39(38.6)</td>
                                    <td>40(38.8)</td>
                                    <td>79(38.7)</td>
                                    <td>46(44.7)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Moderate (w/ pneumonia)</td>
                                    <td class="bd-blue"><b class="p-bl">182 (59.3)</b></td>
                                    <td>62 (61.4)</td>
                                    <td>63 (61.2)</td>
                                    <td>125 (61.3)</td>
                                    <td>57 (55.3)</td>
                                </tr>
                                <tr>
                                    <td class="cate" colspan="6">Age</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Age ≥ 60 Moderate</td>
                                    <td>59 (19.2)</td>
                                    <td>19 (18.8)</td>
                                    <td>21 (20.4)</td>
                                    <td>40 (19.6)</td>
                                    <td>19 (18.4)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Age ≥ 50 Moderate</td>
                                    <td>118 (38.4)</td>
                                    <td>40 (39.6)</td>
                                    <td>40 (38.8)</td>
                                    <td>80 (39.2)</td>
                                    <td>38 (36.9)</td>
                                </tr>
                                <tr>
                                    <td class="cate" colspan="6">Day 1 Viral Load Titre (log<span
                                            class="s-txt">10</span>cp/mL)
                                    </td>
                                </tr>
                                <tr>
                                    <td class="cate2">All Patients</td>
                                    <td>6.4</td>
                                    <td>6.7</td>
                                    <td>6.6</td>
                                    <td>6.7</td>
                                    <td>6.0</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Moderate (w/ pneumonia)</td>
                                    <td>6.1</td>
                                    <td>6.4</td>
                                    <td>6.2</td>
                                    <td>6.2</td>
                                    <td>5.5</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                    <p class="extranote">
                        *Total number (ITTI set) is 307.<br> <sup>&dagger;</sup>Regdanvimab is not approved for use at
                        doses of 80 mg/kg<sup>3</sup></p>
                </div>
            </div>
            <!--Study Results-->
            <div class="cont-sec">
                <h3 class="sub-tit3">Efficacy</h3>
                <div class="cont-indt">
                    <p class="cont-indt">Proportion of patients with clinical symptoms
                        requiring hospitalisation, oxygen therapy or experiencing mortality
                        due to SARS-CoV-2 infection up to Day 28</p>
                    <p class="cont-indt">Treatment with regdanvimab achieved a relative risk reduction by over 50% when
                        compared to placebo in
                        reducing the progression rate to severe COVID-19.</p>
                </div>

                <div class="cont-box cont-indt">
                    <ul class="cont-list">
                        <li>Regdanvimab reduced the progression rate to severe COVID-19 by
                            over 50% when compared to placebo. The difference in events rate
                            was even greater in moderate SARS-CoV-2 infected patients aged ≥50
                            years.
                        </li>
                    </ul>
                    <div class="img-sec mgt20" style="text-align:left;"><img src="/img/providers/eff-table.png"></div>
                    <p style="font-weight: normal; font-size: 14px;"><sup>*</sup>Regdanvimab is not approved for use at
                        doses of 80 mg/kg<sup>3</sup></p>
                </div>
            </div>
            <!--Efficacy-->
            <div class="cont-sec">
                <div class="cont-box cont-indt">
                    <h4 class="sub-tit2 mg10">Time to Clinical Recovery up to Day 14</h4>
                    <ul class="cont-list">
                        <li>All patients treated with regdanvimab reported significantly shortened time to clinical
                            recovery<sup>&dagger;</sup> compared to placebo-treated patients</li>
                        <li>The difference in recovery between regdanvimab- and placebo-treated patients was highest in
                            patients with moderate SARS-CoV-2 infection aged &ge;50 years (6.6 days vs 13.0 days)</li>
                    </ul>
                    <div class="img-sec mgt20" style="text-align:left;"><img src="/img/providers/eff-table2.png"></div>

                    <div class="extranote">
                        <p>*P-value according to log-rank test results</p>
                        <p>†Clinical recovery is defined by all symptoms on the SARS-CoV-2
                            Infection Symptom Checklist (consists of 7 symptoms and the
                            intensity of patient’s self-aware for each symptom)
                            are recorded as “absent or mild in intensity” for at least 24
                            hours.</p>
                        <p><sup>*</sup>Regdanvimab is not approved for use at
                            doses of 80 mg/kg<sup>3</sup></p>
                    </div>

                </div>
            </div>
            <!---->
            <div class="cont-sec">
                <div class="cont-box cont-indt">
                    <h4 class="sub-tit2 mg10">Change from baseline in viral load titre
                        (mean &plusmn; SE)</h4>
                    <ul class="cont-list">
                        <li>Regdanvimab showed greater reductions in baseline viral load and
                            change in viral shedding compared to placebo.
                    </ul>
                    <div class="img-sec mgt20"><img src="/img/providers/eff-graph.png">
                    </div>

                    <p class="extranote"><b>SE</b>, standard error <br>
                        <sup>*</sup>Regdanvimab is not approved for use at doses of 80 mg/kg<sup>3</sup>
                    </p>

                </div>
            </div>
            <!---->
            <div class="cont-sec">
                <h3 class="sub-tit3">Safety<sup>4</sup></h3>
                <div class="cont-box cont-indt">
                    <ul class="cont-list">
                        <li>The overall rate of infusion-related reactions was low, and no
                            treatment-emergent serious adverse events or deaths were reported
                            during the study.
                        </li>
                    </ul>
                    <div class="table-wr">
                        <table class="table-style01">
                            <thead>
                                <tr>
                                    <th colspan="2">N(%)</th>
                                    <th>Regdanvimab<br>40 mg/kg<br>(N=105)</th>
                                    <th>Regdanvimab<br>80 mg/kg<sup>*</sup><br>(N = 110)</th>
                                    <th>Regdanvimab<br>Total<br>(N=215)</th>
                                    <th class="style02">Placebo<br>(N=110)</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td class="cate" rowspan="2">TEAE</td>
                                    <td class="cate2">Total</td>
                                    <td>31 (29.5)</td>
                                    <td>27 (24.5)</td>
                                    <td>58 (27.0)</td>
                                    <td>34 (30.9)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Related</td>
                                    <td>7 (6.7)</td>
                                    <td>5 (4.5)</td>
                                    <td>12 (5.6)</td>
                                    <td>34 (4.5)</td>
                                </tr>
                                <tr>
                                    <td class="cate">TESAE</td>
                                    <td class="cate2">Total</td>
                                    <td>0</td>
                                    <td>0</td>
                                    <td>0</td>
                                    <td>0</td>
                                </tr>
                                <tr>
                                    <td class="cate">TEAEs Classified as IRR</td>
                                    <td class="cate2">Related</td>
                                    <td>1 (1.0)</td>
                                    <td>0</td>
                                    <td>1 (0.5)</td>
                                    <td>2 (1.8)</td>
                                </tr>
                                <tr>
                                    <td class="cate">TEAEs Leading to Permanent<br>Discontinuation
                                        of Study Drug
                                    </td>
                                    <td class="cate2">Total</td>
                                    <td>0</td>
                                    <td>0</td>
                                    <td>0</td>
                                    <td>0</td>
                                </tr>
                            </tbody>
                        </table>
                        <br />
                        <p class="abbreviations"><b>IRR</b>, infusion-related reaction; <b>TEAE</b>,
                            treatment-emergent adverse event; <b>TESAE</b>, treatment-emergent
                            serious adverse event.</p>
                        <p class="extranote"><sup>*</sup>Regdanvimab is not approved for use
                            at doses of 80 mg/kg<sup>3</sup></p>

                        <div class="reference" style="font-weight: normal;">
                            <span class="ref-tit">References</span>:
                            <b>1</b>. Eom J, <em>et al.</em> Therapeutic effect of regdanvimab (CT-P59) in patients with
                            mild to moderate symptoms of SARS CoV-2 infection: Day 28 results from a multicentre,
                            randomised controlled pivotal trial. 2020 High1 Symposia; Limited Access.
                            <b>2</b>. Ison MG, <em>et al.</em> Therapeutic effect of regdanvimab (CT-P59) in patients
                            with mild to moderate symptoms of SARS CoV-2 infection: Day 28 results from a multicentre,
                            randomised controlled pivotal trial. Presented at Keystone Symposia, January 13, 2021,
                            virtual platform. Available at: <a
                                href="https://virtual.keystonesymposia.org/ks/sessions/6866/view"
                                target="_blank">https://virtual.keystonesymposia.org/ks/sessions/6866/view</a>
                            <b>3</b>. Celltrion Healthcare Australia Pty Ltd. REGKIRONA Approved Product Information.
                            December 6, 2021.
                            <b>4</b>. Celltrion Inc. Data on file (MC-59-SP-2M0B1-JL-23-1-0)
                        </div>

                    </div>
                </div>
            </div>
            <!--safety-->
        </div>
    </section>
    <!--sec03-->
    <section id="sec04" class="cont-d el fw-n" style="padding-bottom:0;">
        <div class="inner">
            <h2 class="cont-tit">Part 2 of Phase 2/3 Global Pivotal Study (<a
                    href="https://clinicaltrials.gov/ct2/show/NCT04602000?cond=CT-P59&draw=2&rank=2"
                    style="text-decoration:underline #302f86; color: #302f86;" target="_blank">NCT04602000</a>)<span
                    class="s-num">1</span></h2>
            <p>The approval of regdanvimab was based on interim data from this Phase 3
                study </p>
            <p>&nbsp;</p>
            <div class="cont-sec">
                <h3 class="sub-tit">Study Design</h3>
                <div class="cont-indt">
                    <ul class="cont-list">
                        <li>A randomised, parallel-group, placebo-controlled, double-blind
                            study
                        </li>
                        <li>This study is designed to evaluate the efficacy and safety of
                            regdanvimab in combination with standard of care in outpatients
                            with mild-to-moderate COVID-19 (N = 1315)
                        </li>

                    </ul>
                    <div class="img-sec mgt20"><img src="/img/providers/part_img02.png">
                    </div>
                </div>
                <p>&nbsp;</p>
                <p class="abbreviations"><b>SoC</b>, standard of care. </p>
                <p class="extranote"><sup>*</sup>Regdanvimab is not approved for use at
                    doses of 80 mg/kg<sup>2</sup></p>

            </div>

            <div class="cont-sec">
                <h3 class="sub-tit">Inclusion criteria</h3>
                <div class="cont-box cont-indt">
                    <ul class="cont-list">
                        <li>Adult patients with mild-to-moderate COVID-19</li>
                        <li>Ambulatory (i.e., not hospitalised)</li>
                        <li>At least 1 or more symptom of COVID-19 for &le;7 days</li>
                        <li>Oxygen saturation &gt;94% on room air and not requiring supplemental oxygen therapy</li>
                    </ul>
                </div>
                <p>Patients who had received a COVID-19 vaccine were excluded</p>
            </div>

            <!--Study Design : Part 2-->
            <div class="cont-sec" style="margin-bottom:4em;">
                <h3 class="sub-tit">Primary endpoint</h3>
                <div class="cont-box cont-indt">
                    <ul class="cont-list">
                        <li>Proportion of patients developing severe COVID-19 (defined as requiring hospitalisation,
                            oxygen therapy or dying due to SARS-CoV-2 infection) up to Day 28 in high-risk
                            patients)<sup>*</sup></li>
                    </ul>
                </div>

                <p class="extranote"><sup>*</sup>Defined as having at least one of the
                    following risk factors for severe COVID-19: age &gt;50 years; BMI &gt;30 kg/m<sup>2</sup>;
                    cardiovascular disease, including hypertension; chronic lung disease, including asthma; type 1 or
                    type 2 diabetes mellitus; chronic kidney disease, including those on dialysis; chronic liver
                    disease; and immunosuppressed, based on investigator&rsquo;s assessment</p>

            </div>
            <!--Primary Endpoints-->

            <div class="cont-sec">
                <h3 class="sub-tit">Study Results</h3>
                <h3 class="sub-tit3">Key Demographic Information: Intent-to-Treat
                    Infected (ITTI) set.</h3>
                <div class="cont-box cont-indt">
                    <ul class="cont-list">
                        <li>66% of enrolled patients were deemed high-risk<sup>*</sup></li>
                    </ul>
                    <div class="table-wr">
                        <!-- <table class="table-style01">
                            <thead>
                                <tr>
                                    <th colspan="2"></th>
                                    <th>Total(N=1315)</th>
                                    <th>regdanvimab 40 mg/kg (N=656)</th>
                                    <th>Placebo (N=659)</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td class="cate">Age(years)</td>
                                    <td class="cate2">Median (min-max)</td>
                                    <td>48 (18-87)</td>
                                    <td>49 (18-87)</td>
                                    <td>47 (18-83)</td>
                                </tr>
                                <tr>
                                    <td class="cate" rowspan="2">Sex, n (%)</td>
                                    <td class="cate2">Male</td>
                                    <td>674 (51.3)</td>
                                    <td>347 (52.9)</td>
                                    <td>327 (49.6)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Female</td>
                                    <td>641 (48.7)</td>
                                    <td>309 (47.1)</td>
                                    <td>332 (50.4)</td>
                                </tr>
                                <tr>
                                    <td class="cate" rowspan="6">Race, n (%)</td>
                                    <td class="cate2">White</td>
                                    <td>1132 (86.1)</td>
                                    <td>563 (85.8)</td>
                                    <td>569 (86.3)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Black or African American</td>
                                    <td>7 (0.5)</td>
                                    <td>6 (0.9)</td>
                                    <td>1 (0.2)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">American Indian or<br> Alaska Native</td>
                                    <td>14 (1.1)</td>
                                    <td>5 (0.8)</td>
                                    <td>9 (1.4)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Asian</td>
                                    <td>14 (1.1)</td>
                                    <td>7 (1.1)</td>
                                    <td>7 (1.1)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Native Hawaiian or<br> Other Pacific Islander
                                    </td>
                                    <td>1 (0.1)</td>
                                    <td>1 (0.2)</td>
                                    <td>0</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Other</td>
                                    <td>147 (11.2)</td>
                                    <td>74 (11.3)</td>
                                    <td>73 (11.1)</td>
                                </tr>
                                <tr>
                                    <td class="cate">BMI (kg/m2)</td>
                                    <td class="cate2">Mean (SD)</td>
                                    <td>28.04 (5.369)</td>
                                    <td>28.10 (5.149)</td>
                                    <td>27.98 (5.583)</td>
                                </tr>
                                <tr>
                                    <td class="cate">High-risk, n (%)</td>
                                    <td class="cate2"></td>
                                    <td class="bd-blue"><b class="p-bl">880 (66.9)</b></td>
                                    <td>446 (68.0)</td>
                                    <td>434 (65.9)</td>
                                </tr>
                            </tbody>
                        </table> -->

                        <table class="table-style01">
                            <thead>
                                <tr>
                                    <th colspan="2">&nbsp;</th>
                                    <th>Total (N=1315)</th>
                                    <th>regdanvimab 40 mg/kg (N=656)</th>
                                    <th>Placebo (N=659)</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td class="cate">Age, median (range)</td>
                                    <td class="cate2">Years</td>
                                    <td>48 (18-87)</td>
                                    <td>49 (18-87)</td>
                                    <td>47 (18-83)</td>
                                </tr>
                                <tr>
                                    <td class="cate" rowspan="2">Sex, n (%)</td>
                                    <td class="cate2">Male</td>
                                    <td>674 (51.3)</td>
                                    <td>347 (52.9)</td>
                                    <td>327 (49.6)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Female</td>
                                    <td>641 (48.7)</td>
                                    <td>309 (47.1)</td>
                                    <td>332 (50.4)</td>
                                </tr>
                                <tr>
                                    <td class="cate" rowspan="6">Race, n (%)</td>
                                    <td class="cate2">White</td>
                                    <td>1132 (86.1)</td>
                                    <td>563 (85.8)</td>
                                    <td>569 (86.3)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Black or African American</td>
                                    <td>7 (0.5)</td>
                                    <td>6 (0.9)</td>
                                    <td>1 (0.2)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">American Indian or<br /> Alaska Native</td>
                                    <td>14 (1.1)</td>
                                    <td>5 (0.8)</td>
                                    <td>9 (1.4)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Asian</td>
                                    <td>14 (1.1)</td>
                                    <td>7 (1.1)</td>
                                    <td>7 (1.1)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Native Hawaiian or<br /> Other Pacific Islander</td>
                                    <td>1 (0.1)</td>
                                    <td>1 (0.2)</td>
                                    <td>0</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Other</td>
                                    <td>147 (11.2)</td>
                                    <td>74 (11.3)</td>
                                    <td>73 (11.1)</td>
                                </tr>
                                <tr>
                                    <td class="cate">BMI, mean (SD)</td>
                                    <td class="cate2">kg/m2</td>
                                    <td>28.04 (5.369)</td>
                                    <td>28.10 (5.149)</td>
                                    <td>27.98 (5.583)</td>
                                </tr>
                                <tr>
                                    <td class="cate">High-risk, n (%)</td>
                                    <td class="cate2">&nbsp;</td>
                                    <td class="bd-blue"><b class="p-bl">880 (66.9)</b></td>
                                    <td>446 (68.0)</td>
                                    <td>434 (65.9)</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                    <p class="extranote">BMI; basal metabolic index; SD, standard
                        deviation<br /> *High-risk patients were those with &ge;1 of the following risk factors: age
                        &gt;50 years, BMI &gt; 30 kg/m&sup2;, cardiovascular disease (including hypertension), chronic
                        kidney disease (including those on dialysis), chronic lung disease (including asthma),
                        non-severe pneumonia, chronic metabolic disease (including diabetes), chronic liver disease,
                        immunosuppressed.</p>
                </div>


            </div>
            <!---->
            <div class="cont-sec">
                <h3 class="sub-tit3">Efficacy</h3>
                <div class="cont-box cont-indt">
                    <p>Progression to severe COVID-19<sup>&dagger;</sup> was&nbsp;<b>reduced by 72% in high-risk
                            patients<sup>*</sup></b>&nbsp;treated with regdanvimab compared to placebo at Day 28
                        (p&lt;0.0001)</p>
                    <h4 class="sub-tit2"><b>Proportion of patients progressing to severe
                            COVID-19<sup>&dagger;</sup> up to day 28, n/N (%)<sup>3</sup></b></h4>
                    <div class="table-wr">

                        <table class="table-style01">
                            <thead>
                                <tr>
                                    <th>&nbsp;</th>
                                    <th>Regdanvimab 40mg/kg</th>
                                    <th class="style02">Placebo</th>
                                    <th class="style03">Relative risk reduction (95% CI)</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td class="cate">High-risk Patients n/N (%)</td>
                                    <td class="cate2">14/446 (3.1%)</td>
                                    <td>48/434 (11.1%)</td>
                                    <td class="bd-blue"><b class="p-bl">72.3%</b><br />(50.4&ndash;84.5)
                                        p&lt;0.0001<br /><br /></td>
                                </tr>
                                <tr>
                                    <td class="cate">All Patients n/N (%)</td>
                                    <td class="cate2">16/656 (2.4%)</td>
                                    <td>53/659 (8.0%)</td>
                                    <td class="bd-blue" style="border-bottom: 3px solid #055fad!important;"><b
                                            class="p-bl">70%</b></td>
                                </tr>
                            </tbody>
                        </table>
                        <br>
                        <p class="extranote">CI, confidence interval
                            <br><sup>&dagger;</sup>Defined as clinical symptoms requiring hospitalisation, oxygen
                            therapy, or experiencing mortality due to SARS-CoV-2 infection up to Day 28
                            <br>*High-risk patients were those with &ge;1 of the following risk factors: age &gt;50
                            years, BMI &gt; 30 kg/m&sup2;, cardiovascular disease (including hypertension), chronic
                            kidney disease (including those on dialysis), chronic lung disease (including asthma),
                            non-severe pneumonia, chronic metabolic disease (including diabetes), chronic liver disease,
                            immunosuppressed
                        </p>

                    </div>
                    <h4 class="sub-tit2">Time to Clinical Recovery up to Day 14</h4>
                    <ul class="cont-list">
                        <li>The median time to clinical recovery<sup>&para;</sup> in high-risk patients* treated with
                            regdanvimab was&nbsp;<b>9.3 days,</b>&nbsp;which was <b>4.7 days
                                shorter</b>&nbsp;than patients who received placebo (p&lt;0.0001)</li>
                        <li>The median time to clinical recovery<sup>&para;</sup> among all patients was <b>4.9
                                days shorter</b>&nbsp;in patients who received regdanvimab than patients who
                            received placebo (p&lt;0.0001)</li>
                    </ul>
                    <p>&nbsp;</p>
                    <h4 class="sub-tit2"><b>Median Time to Clinical Recovery</b><b><sup>3</sup></b><sup>&para;</sup>
                    </h4>
                    <div class="table-wr">

                        <table class="table-style01">
                            <thead>
                                <tr>
                                    <th>&nbsp;</th>
                                    <th>Regdanvimab 40 mg/kg<br />(n = 446)</th>
                                    <th class="style02">Placebo<br />(n = 434)</th>
                                    <th class="style02">
                                        <p>Clinical recovery ratio&dagger; (95% CI)</p>
                                    </th>
                                    <th class="style03">P-value</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td class="cate">High-risk Patients n/N (%)</td>
                                    <td class="cate2">9.3</td>
                                    <td>14.0*</td>
                                    <td>1.58 (1.31, 1.90)</td>
                                    <td class="bd-blue">p&lt;0.0001</td>
                                </tr>
                                <tr>
                                    <td class="cate">All Patients n/N (%)</td>
                                    <td class="cate2">8.4</td>
                                    <td>13.3</td>
                                    <td>1.50 (1.29, 1.73)</td>
                                    <td class="bd-blue" style="border-bottom: 3px solid #055fad!important;">p&lt;0.0001
                                    </td>
                                </tr>
                            </tbody>
                        </table>
                        <br>
                        <p class="extranote">CI, confidence interval. <br>
                            <sup>&para;</sup>Defined as time from study drug administration to the time when symptoms,
                            which were scored as &lsquo;moderate&rsquo; or &lsquo;severe&rsquo; at baseline reduced to
                            &lsquo;mild&rsquo; or &lsquo;absent&rsquo;, and symptoms scored as &lsquo;mild&rsquo; or
                            &lsquo;absent&rsquo; at baseline were scored as &lsquo;absent&rsquo;. Symptoms
                            &lsquo;absent&rsquo; in intensity at baseline should maintain as &lsquo;absent&rsquo; for at
                            least 48 hours. Symptoms that were absent at baseline but became &lsquo;severe&rsquo;,
                            &lsquo;moderate&rsquo;, or &lsquo;mild&rsquo; in intensity during the study were considered
                            clinically recovered if it changed back to &lsquo;absent&rsquo; for at least 48 hours.
                            Symptoms assessed were limited to feeling feverish, cough, shortness of breath or difficulty
                            breathing, sore throat, body pain or muscle pain, fatigue, and headache
                            <br>
                            *High-risk patients were those with &ge;1 of the following risk factors: age &gt;50 years,
                            BMI &gt; 30 kg/m&sup2;, cardiovascular disease (including hypertension), chronic kidney
                            disease (including those on dialysis), chronic lung disease (including asthma), non-severe
                            pneumonia, chronic metabolic disease (including diabetes), chronic liver disease,
                            immunosuppressed
                            <br>
                            <sup>&sect;</sup>Not calculated. The number of patients who achieved clinical recovery up to
                            Day 14 was less than 50%.
                            <br>
                            <sup>&dagger;</sup>Estimated ratio from stratified Cox proportion hazard model.
                        </p>
                    </div>
                </div>
            </div>
            <!---->
            <div class="cont-sec">
                <h3 class="sub-tit3">Mean (&plusmn; SE) change from baseline of viral load titre (ITTI set)3</h3>
                <div class="cont-indt">
                    <p style="padding-left: 20px;">Greater reduction from baseline viral load were shown in the
                        regdanvimab 40 mg/kg group compared to the placebo group at Day 7.</p>
                </div>
                <div class="cont-box cont-indt">
                    <div class="img-sec"><img src="/img/providers/graph_img02.jpg"></div>
                    <p class="extranote">ITTI, intention-to-treat infected; SE, standard
                        error</p>
                </div>

            </div>
            <div class="cont-sec">
                <h3 class="sub-tit3">Safety</h3>
                <div class="cont-box cont-indt">
                    <p>There were no clinical meaningful differences in safety results
                        between the regdanvimab and placebo groups</p>
                    <h4 class="sub-tit2"><b>Summary of adverse events up to Day 28<sup>3</sup></b></h4>
                    <div class="table-wr">

                        <table class="table-style01">
                            <thead>
                                <tr>
                                    <th>&nbsp;</th>
                                    <th>Number of patients, n (%)</th>
                                    <th>Regdanvimab 40 mg/kg <br />(N = 652)</th>
                                    <th class="style02">Placebo <br />(N = 650)</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td class="cate" rowspan="2">&ge; 1 TEAE</td>
                                    <td class="cate2">Total</td>
                                    <td>198 (30.4)</td>
                                    <td>202 (31.1)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Related</td>
                                    <td>44 (6.7)</td>
                                    <td>46 (7.1)</td>
                                </tr>
                                <tr>
                                    <td class="cate" rowspan="3">&ge; 1 TESAE</td>
                                    <td class="cate2">Total</td>
                                    <td>4 (0.5)</td>
                                    <td>1 (0.1)</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Related</td>
                                    <td>1 (0.2)</td>
                                    <td>0</td>
                                </tr>
                                <tr>
                                    <td class="cate2">Unrelated</td>
                                    <td>3 (0.5)</td>
                                    <td>1 (0.2)</td>
                                </tr>
                                <tr>
                                    <td class="cate">&ge; 1 TEAE Classified as IRR*</td>
                                    <td class="cate2">Total</td>
                                    <td>4 (0.6)</td>
                                    <td>7 (1.1)</td>
                                </tr>
                                <tr>
                                    <td class="cate">TEAEs Leading to Study Drug Discontinuation</td>
                                    <td class="cate2">Total</td>
                                    <td>0</td>
                                    <td>0</td>
                                </tr>
                            </tbody>
                        </table>
                        <br>
                        <p class="abbreviations" style="font-weight: normal"><b>IRR</b>, infusion-related reaction;
                            <b>TEAE</b>,
                            treatment-emergent adverse event; <b>TESAE</b>, treatment-emergent
                            serious adverse event.
                        </p>
                        <p class="extranote">*All events were Grade 1 or 2, and all patients
                            from both groups recovered during the treatment period</p>
                    </div>



                    <div class="reference " style="font-weight: normal;">
                        <span class="ref-tit">References</span>:
                        <b>1</b>. Ison MG, <em>et al.</em> Therapeutic effect of regdanvimab in patients with mild to
                        moderate COVID-19: day 28 results from a multi-centre, randomised, controlled pivotal trial.
                        Presented at the 31st European Congress of Clinical Microbiology &amp; Infectious Diseases, July
                        9-12, 2021, Vienna, Austria
                        <b>2</b>. Celltrion Healthcare Australia Pty Ltd. REGKIRONA Approved Product Information.
                        December 6, 2021.
                        <b>3</b>. Sandulescu, O. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate
                        COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial. Oral
                        presentation at the 31st European Congress of Clinical Microbiology &amp; Infectious Diseases.
                        July 2021.
                    </div>

                </div>

            </div>
            <!---->

        </div>
    </section>
    <!--sec04-->
    <section id="sec05" class="cont-a el fw-n">
        <div class="inner">
            <h2 class="cont-tit"><b>Neutralising capability against emerging variants (<em>in
                        vitro</em>)<sup>1&ndash;4</sup></b></h2>
            <div class="cont-sec">
                <ul class="cont-list cont-indt">
                    <li>Plaque reduction neutralising tests (PRNT) using authentic SARS-CoV-2 variant virus indicate
                        that regdanvimab retained activity against the Alpha (UK origin/B.1.1.7 lineage), Zeta
                        (Brazilian origin/P.2), Iota (New York origin/B.1.526) and Eta (Nigerian origin/B.1.525)
                        variants</li>
                    <li>Microneutralisation data using authentic SARS-CoV-2 variant virus indicate that regdanvimab
                        retains activity against the Alpha variant (1.4-fold change in IC<sub>50</sub>&nbsp;value) and
                        reduced potency against the Beta (19.75-fold change in IC<sub>50</sub>&nbsp;value) and Gamma
                        (137.88-fold change in IC<sub>50</sub>&nbsp;value) variants</li>
                </ul>
            </div>

            <div class="cont-box cont-indt" style="margin-bottom:0;">
                <div class="table-wr">

                    <table class="table-style01">
                        <thead>
                            <tr>
                                <th>World Health<br />Organisation<br />(WHO) Label</th>
                                <th>Lineage with<br />Spike Protein<br />Substitution</th>
                                <th>Key Substitutions<br />Tested<span class="s-txt">a</span></th>
                                <th>Fold Reduction<br />in Susceptibility<br />(Authentic Virus)</th>
                                <th>Fold Reduction<br />in Susceptibility<br />(Pseudovirus)</th>
                                <th>Animal Test<br />(Treatment Efficacy)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td class="cate">Alpha</td>
                                <td class="cate">B.1.1.7 (UK)</td>
                                <td class="cate">N501Y/P681H</td>
                                <td class="cate">No change<sup>b, d, e</sup></td>
                                <td class="cate">No change<sup>b</sup></td>
                                <td class="cate">-</td>
                            </tr>
                            <tr>
                                <td>Beta</td>
                                <td>B.1.351 (South Africa)</td>
                                <td>K417N+E484K+N501Y</td>
                                <td>20<sup>e</sup>&nbsp;/ 310<sup>d</sup></td>
                                <td>184/253</td>
                                <td>Similar with wild-type<sup>1</sup></td>
                            </tr>
                            <tr>
                                <td class="cate">Gamma</td>
                                <td class="cate">P.1 (Brazil)</td>
                                <td class="cate">K417T/E484K/N501Y</td>
                                <td class="cate">138<sup>e</sup>/168<sup>d</sup></td>
                                <td class="cate">61/127</td>
                                <td class="cate">Similar with wild-type<sup>2</sup></td>
                            </tr>
                            <tr>
                                <td>Delta</td>
                                <td>B.1.167.2 (India)</td>
                                <td>L452R/T478K/P681R</td>
                                <td>183</td>
                                <td>28</td>
                                <td>Similar with wild-type<sup>3</sup></td>
                            </tr>
                            <tr>
                                <td class="cate">Epsilon</td>
                                <td class="cate">B.1.427 (California)</td>
                                <td class="cate">L452R</td>
                                <td class="cate">74<sup>d</sup></td>
                                <td class="cate">Not determined</td>
                                <td class="cate">-</td>
                            </tr>
                            <tr>
                                <td>Epsilon</td>
                                <td>B.1.429 (California)</td>
                                <td>L452R</td>
                                <td>54<sup>d</sup></td>
                                <td>31</td>
                                <td>-</td>
                            </tr>
                            <tr>
                                <td class="cate">Zeta</td>
                                <td class="cate">P.2 (Brazil)</td>
                                <td class="cate">E484K</td>
                                <td class="cate">No change<sup>b, d</sup></td>
                                <td class="cate">Not determined</td>
                                <td class="cate">-</td>
                            </tr>
                            <tr>
                                <td>Eta</td>
                                <td>B.1.525 (Nigeria)</td>
                                <td>E484K/Q766H</td>
                                <td>No change<sup>b, d</sup></td>
                                <td>7</td>
                                <td>-</td>
                            </tr>
                            <tr>
                                <td class="cate">lota</td>
                                <td class="cate">B.1.526<span class="s-txt">c</span></td>
                                <td class="cate">E484K</td>
                                <td class="cate">No change<span class="s-txt">b, d</span></td>
                                <td class="cate">7</td>
                                <td class="cate">-</td>
                            </tr>
                            <tr>
                                <td rowspan="4">Kappa</td>
                                <td>B.1.617.1 (India)</td>
                                <td>L452R/E484Q/P681R</td>
                                <td>24<sup>d</sup></td>
                                <td>44</td>
                                <td>-</td>
                            </tr>
                            <tr>

                                <td>AY.1 (India)</td>
                                <td>K417n/l452r/t478k</td>
                                <td>Not determined</td>
                                <td>64</td>
                                <td>&nbsp;</td>
                            </tr>
                            <tr>

                                <td>C.37 (Peru)</td>
                                <td>L452Q/F490S</td>
                                <td>Not determined</td>
                                <td>16</td>
                                <td>&nbsp;</td>
                            </tr>
                            <tr>

                                <td>B.1.621 (Columbia)</td>
                                <td>R346K/E484K/N501Y/P681H</td>
                                <td>Not determined</td>
                                <td>39</td>
                                <td>&nbsp;</td>
                            </tr>
                        </tbody>
                    </table>
                    <p>&nbsp;</p>
                    <p class="extranote"><sup>a</sup>For variants with more than one
                        substitution of concern, only the one(s) with the greatest impact on activity is(are)
                        listed<br /><sup>b</sup>No change: &lt;5-fold reduction in susceptibility<br /><sup>c</sup>Not
                        all isolates of the Iota lineage harbors E484K substitution (as of February
                        2021)<br /><sup>d</sup>The study was conducted using plaque reduction neutralisation
                        test<br /><sup>e</sup>The study was conducted using microneutralisation
                        assay<br /><sup>f</sup>Key substitutions for global variants have been tested in a pseudovirus
                        assay and multiple studies have been conducted for some variants</p>
                    <p>&nbsp;</p>
                    <div class="reference fw-n">
                        <span class="ref-tit">References</span>: <strong>1</strong>. Ryu DK, et al. Biochem. Biophys.
                        Commun. 2021;566:135-140. <strong>2</strong>. Ryu DK, et al. bioRxiv., [Preprint] <a
                            href="https://doi.org/10.1101/2021.07.08.451696" target="_blank"
                            rel="noopener">https://doi.org/10.1101/2021.07.08.451696</a> <strong>3</strong>. Ryu DK, et
                        al. bioRxiv., [Preprint] <a href="https://doi.org/10.1101/2021.07.23.453472" target="_blank"
                            rel="noopener">https://doi.org/10.1101/2021.07.23.453472</a> <strong>4</strong>. Celltrion
                        Healthcare Australia Pty Ltd. REGKIRONA Approved Product Information. December 6, 2021.
                    </div>

                </div>
            </div>
        </div>
    </section>
    <!--sec05-->
    <section id="sec06" class="cont-d el fw-n">
        <div class="cont-sec inner mb-0 pb-0">
            <h2 class="cont-tit">Neutralising capability against emerging variants (<em>in vivo</em> animal studies)
            </h2>
            <div class="cont-sec">
                <h3 class="sub-tit p-gr"><em>In vivo</em> efficacy test against Beta (B.1.351) variant<sup>1</sup></h3>
                <ul class="cont-list cont-indt mg20">
                    <li>Therapeutic dosage of regdanvimab showed <em>in vivo</em> neutralising potency against the Beta
                        (B.1.351) variant in the ferret challenge study</li>
                    <li>Virus titres in the upper respiratory tract significantly decreased following regdanvimab
                        treatment similarly for both viruses (Beta and S clades) in the median tissue culture infectious
                        dose (TCID<sub>50</sub>) assay, where only the replicating virus is quantified</li>
                </ul>
                <div class="cont-box cont-indt" style="text-align:center;">
                    <img src="/img/providers/mono_g01.png">
                    <br><br>
                    <p class="extranote text-left">TCID<sub>50</sub>; median tissue culture infectious
                        dose<br /><sup>&dagger;</sup>Regdanvimab is not approved for use at doses of 80 mg/kg and 160
                        mg/kg<sup>2</sup></p>
                </div>

                <div class="cont-indt">

                    <p>Ferrets challenged with either B.1.351 or wild type
                        showed a decrease in body weight by about 5% in the control group, while there was no weight
                        loss in the regdanvimab administered groups</p>
                </div>

                <div class="cont-box cont-indt" style="text-align:center;">
                    <p><b> &lt;Weight changes during <em>in vivo</em> efficacy
                            evaluations in ferret model&gt;</b></p>
                    <img src="/img/providers/ferret-model.png">

                </div>

                <div class="cont-indt">
                    <p>The body weights were daily measured for control group (vehicle) and regdanvimab treated groups
                        (80 mg/kg and 160 mg/kg). The mean body weight changes were calculated based on individual
                        baseline body weight from ferrets challenged with B.1.351 (A) and wild type virus (B). Asterisk
                        or pound indicates statistical significance between the control and each group as determined by
                        one-way ANOVA and post-hoc Dunnett&rsquo;s <em>test</em>. (* indicates <em>P </em>&lt; 0.05 in
                        control vs 80 mg/kg and control vs. 160 mg/kg, # indicates P &lt; 0.05 in control vs 160 mg/kg).
                        Regdanvimab is not approved for use at doses of 80 mg/kg and 160 mg/kg<sup>2</sup></p>

                    <p>There were minimal to mild clinical symptoms after regdanvimab administration until 3 dpi;
                        however, no clinical signs were observed from 4 dpi, except one animal challenged with SA
                        variant</p>
                    <br>

                    <div class="reference">
                        <span class="ref-tit">References</span>:
                        <b>1</b>. Ryu DK, et al. Biochem. Biophys. Res. Commun. 2021;566:135-140.
                        <b>2</b>. Celltrion Healthcare Australia Pty Ltd. REGKIRONA Approved Product Information.
                        December 6, 2021.
                    </div>

                </div>
            </div>
        </div>
        <div class="cont-sec inner mb-0 pb-0">
            <h3 class="sub-tit p-gr"><em>In vivo</em> efficacy test against gamma (P.1) variant<sup>1</sup></h3>
            <ul class="cont-list cont-indt mg20">
                <li>Regdanvimab showed a significant decrease in viral load in the lungs of hACE2 TG mice 8 hours after
                    viral challenge</li>
                <li>All the mice treated with regdanvimab showed limit of quantification (LOQ) in viral load at 6 days
                    post infusion (dpi)</li>
            </ul>
            <div class="cont-box cont-indt" style="text-align:center;">
                <img src="/img/providers/mono_g02.png">
                <br><br>
                <p style="font-weight: normal; font-size: 14px; text-align:left;">dpi, days post-infusion; PFU;
                    plaque-forming units</p>
                <p style="font-weight: normal; font-size: 14px; text-align:left;">&dagger;Regdanvimab is not approved
                    for use at doses of 5, 20, 80 mg/kg<sup>2</sup></p>
            </div>
            <ul class="cont-list cont-indt mg20">
                <li>During the follow-up period, mice treated with regdanvimab showed
                    significant protection from weight loss from 2 dpi.
                </li>
            </ul>
            <div class="cont-box cont-indt" style="text-align:center;">
                <img src="/img/providers/mono_g03.png">
                <br> <br>
                <p style="font-weight: normal; font-size: 14px; text-align:left;"><sup>&dagger;</sup>Regdanvimab is not
                    approved for use at doses of 5, 20, 80 mg/kg<sup>2</sup></p>
            </div>
            <ul class="cont-list cont-indt mg20">
                <li>100% survival rates were observed in mice treated with regdanvimab,
                    while mice treated with placebo showed 0% survival rate from 6 dpi.
                </li>
            </ul>
            <div class="cont-box cont-indt mg20" style="text-align:center;">
                <img src="/img/providers/mono_g04.png">
                <p style="font-weight: normal; font-size: 14px; text-align:left;"><sup>&dagger;</sup>Regdanvimab is not
                    approved for use at doses of 5, 20, 80 mg/kg<sup>2</sup></p>

                <div class="reference" style="text-align:left; font-weight: normal">
                    <span class="ref-tit">References</span>:
                    <b>1</b>. Ryu DK, <em>et al. bioRxiv.,</em> [Preprint] <a
                        href="https://doi.org/10.1101/2021.07.23.453472"
                        target="_blank">https://doi.org/10.1101/2021.07.23.453472</a>.
                    <b>2</b>. Celltrion Healthcare Australia Pty Ltd. REGKIRONA Approved Product Information. December
                    6, 2021.
                </div>

            </div>
        </div>
        <div class="cont-sec inner">
            <h3 class="sub-tit p-gr"><em>In vivo</em> Efficacy Test Against Delta (B.1.167.2)
                Variant<span class="s-txt">1</span></h3>
            <ul class="cont-list cont-indt mg20">
                <li>Regdanvimab showed significant decreases in viral load in the lungs of mice 8 hours after viral
                    challenge, with virus eradication from all mice treated with 20 mg/kg and 80 mg/kg at 3 days
                    post-inoculation (dpi)</li>
                <li>All the mice treated with regdanvimab 5 to 80 mg/kg (clinically equivalent to 2.5 to 40 mg/kg for
                    human dose) showed limit of quantitation (LOQ) in viral load at 6 dpi</li>
            </ul>
            <div class="cont-box cont-indt mg20" style="text-align:center;">
                <img src="/img/providers/mono_g05.png">
                <br><br>
                <p style="font-weight: normal; font-size: 14px; text-align: left">Dpi, days post-inoculation; LOQ, limit
                    of quantitation <br />&dagger;Regdanvimab is not approved for use at doses of 5, 20, 80 mg/kg2</p>
            </div>

            <ul class="cont-list cont-indt mg20">
                <li>During the follow-up period, mice treated with regdanvimab showed
                    significant protection from weight loss at 3 dpi and thereafter.
                </li>
            </ul>
            <div class="cont-box cont-indt mg20" style="text-align:center;">
                <img src="/img/providers/mono_g06.png"><br><br>
                <p style="font-weight: normal; font-size: 14px; text-align: left"><sup>&dagger;</sup>Regdanvimab is not
                    approved for use at doses of 5, 20, 80 mg/kg<sup>2</sup></p>
            </div>
            <ul class="cont-list cont-indt mg20">
                <li>100% survival rates were observed in mice treated with regdanvimab,
                    while mice treated with placebo showed 0% survival rate from 6 dpi.
                </li>
            </ul>
            <div class="cont-box cont-indt mg20" style="text-align:center;">
                <img src="/img/providers/mono_g07.png">
                <p style="font-weight: normal; font-size: 14px; text-align:left;"><sup>&dagger;</sup>Regdanvimab is not
                    approved for use at doses of 5, 20, 80 mg/kg<sup>2</sup></p>
            </div>
        </div>
    </section>
    <!--sec06-->
    <section id="sec07" class="cont-c el pt-0 fw-n">
        <div class="inner">
            <h2 class="cont-tit">References</h2>
            <ul class="nb-list">
                <li>
                    <span>1.</span> Ryu DK, <em>et al.</em> The in vitro and in vivo potency of CT-P59 against Delta and
                    its associated variants of SARS-CoV-2. bioRxiv., 2021.07.23.453472; doi:
                    <a href="https://doi.org/10.1101/2021.07.23.453472" target="_blank"
                        rel="noopener">https://doi.org/10.1101/2021.07.23.453472</a>
                </li>
                <li>
                    <span>2.</span> Celltrion Healthcare Australia Pty Ltd. REGKIRONA Approved Product Information.
                    December 6, 2021.
                </li>
            </ul>
        </div>
    </section>
    <!--sec07-->
</div>
<?php
include_once(G5_PATH . '/footer.php');
?>